(NASDAQ: ANTX) An2 Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 25.29%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 1,459.85%.
An2 Therapeutics's earnings in 2026 is -$35,174,000.On average, 3 Wall Street analysts forecast ANTX's earnings for 2026 to be -$33,360,617, with the lowest ANTX earnings forecast at -$32,052,358, and the highest ANTX earnings forecast at -$34,341,812.
In 2027, ANTX is forecast to generate -$29,328,015 in earnings, with the lowest earnings forecast at -$28,177,897 and the highest earnings forecast at -$30,190,604.